PT2:06 Obinutuzumab induces histological remission and deep kidney parenchymal B-cell depletion in patients with lupus nephritis: exploratory analyses of the phase III regency trial

Lupus Science & Medicine 2026 Open access

Read full text
Authors: Brad H. Rovin, Elsa Martins, Cary D. Austin, Harini Raghu, Caleb C. Y. Chan, Patrick S. Chang, Jay P Garg, Valeria Gabriela Alberton, MB Santiago, Gustavo Aroca-Martinez, Fedra Irazoque Palazuelos, Teresa Bączkowska
+13 more José Alfaro, Jorge Ravelo-Hernández, Richard Alan Furie, Pinto Lf, Eduardo Horacio Albiero, Christopher Larsen, Bongin Yoo, Jennifer Pulley, Andrew J. Thorley, Thomas Hellmut Schindler, Theodore A. Omachi, William F. Pendergraft, Ana Malvar
DOI: 10.1136/lupus-2026-el.37
Cited by: 0

Abstract

Objectives The REGENCY trial ( NCT04221477) demonstrated superiority of obinutuzumab (OBI) plus standard therapy (+ST) vs placebo (PBO) +ST in achieving complete renal response (CRR) at Week 76 (W76) in adults with active lupus nephritis (LN). These exploratory analyses aimed to evaluate histological remission and kidney tissue-level B-cell depletion at W76 in patients treated with OBI+ST vs PBO+ST.Methods Paired baseline and W76 kidney biopsies from REGENCY participants with biopsy-proven proliferative LN were analysed. Histological analysis: 64 biopsies (32 OBI+ST, 32 PBO+ST) were evaluated using the 2018 ISN/RPS LN classification, along with the NIH activity (AI) and chronicity indices. The proportion of patients achieving histological or near-histological remission (AI=0 or

Fields of Study & Subjects

Systemic Lupus Erythematosus Research Renal Diseases and Glomerulopathies Renal Transplantation Outcomes and Treatments

Publication details

Journal / source
Lupus Science & Medicine
Pages
A38–A39
Publication date
1 March 2026
Language
EN